Skip to main content
. 2014 Dec;99(12):1817–1825. doi: 10.3324/haematol.2014.111203

Figure 1.

Figure 1.

Survival of patients with primary mediastinal large B-cell lymphoma. (A) Overall survival (OS) of all patients with primary mediastinal large B-cell lymphoma (PMBL). (B) Progression-free survival (PFS) of all patients with PMBL. (C) OS of patients with PMBL treated with CHOP (n=44), R-CHOP (n=188), DA-EPOCH-R (n=9), 2nd- or 3rd-generation regimens (n=45), and HDT/ASCT (n=57). (D) PFS of patients with PMBL treated with CHOP (n=44), R-CHOP (n=188), DA-EPOCH-R (n=9), 2nd- or 3rd-generation regimens (n=45), and HDT/ASCT (n=57). CHOP: cyclophosphamide, adriamycin, vincristine and prednisone; R: rituximab; DA-EPOCH-R: dose-adjusted etoposide, cyclophosphosphamide, doxorubicin, vincristine, prednisolone and rituximab; HDT/ASCT: high-dose chemotherapy followed by autologous stem cell transplantation.